USA – API supply from China is stable, FDA says

With pharmaceutical supply chains under immense pressure due to the novel coronavirus, China’s role as a global ingredient producer has come under scrutiny. Despite fears the East Asian nation could shut off the tap for U.S. drugs, the FDA said it hasn’t yet noticed major signs for concern.

The FDA hasn’t seen a shortage of active pharmaceutical ingredients (APIs) sourced from China due to the ongoing novel coronavirus outbreak but is « closely monitoring the situation, » FDA Commissioner Stephen Hahn told Fox News on Sunday.

« We don’t have any evidence that there’s a drug in short supply because of anyone blocking the active pharmaceutical ingredients coming to us (from China), » Hahn said…